<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39472619</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients.</ArticleTitle><Pagination><StartPage>25901</StartPage><MedlinePgn>25901</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25901</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76472-0</ELocationID><Abstract><AbstractText>Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain. This retrospective cohort study assessed the effect of nirmatrelvir-ritonavir in preventing severe disease progression and long COVID symptoms after acute COVID-19 in non-hospitalized adults. SALAMA medical records from Dubai's COVID-19 healthcare centers between May 22, 2022, and April 30, 2023, were used to identify 7290 eligible patients, 9.6% of whom received nirmatrelvir-ritonavir. Treatment was associated with a notable reduction in COVID-19-related hospitalizations (adjusted hazard ratio [HR] of 0.39; 95% CI, 0.18-0.85) by day 28 of symptom onset. Moreover, nirmatrelvir-ritonavir was associated with fewer long COVID symptoms (adjusted HR of 0.42; 95% CI, 0.19-0.95). This suggests the significant effectiveness of nirmatrelvir-ritonavir against the Omicron variant, reducing both severe and long-term COVID-19 symptoms.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Saheb Sharif-Askari</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ali Hussain Alsayed</LastName><ForeName>Hawra</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Rashid Hospital, Dubai Academic Health Corporation, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saheb Sharif-Askari</LastName><ForeName>Narjes</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Sayed Hussain</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Dubai Health Authority, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Muhsen</LastName><ForeName>Saleh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Immunology Research Laboratory, Department of Pediatrics, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halwani</LastName><ForeName>Rabih</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates. rhalwani@sharjah.ac.ae.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. rhalwani@sharjah.ac.ae.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine, Prince Abdullah Ben Khaled Celiac Disease Chair, King Saud University, Riyadh, Saudi Arabia. rhalwani@sharjah.ac.ae.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>7R9A5P7H32</RegistryNumber><NameOfSubstance UI="C000718217">nirmatrelvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007769">Lactams</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007769" MajorTopicYN="N">Lactams</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Nirmatrelvir&#x2013;ritonavir</Keyword><Keyword MajorTopicYN="N">Omicron variant</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>10</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>10</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39472619</ArticleId><ArticleId IdType="pmc">PMC11522512</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76472-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76472-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>http://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html, A.J., 2023.</Citation></Reference><Reference><Citation>Sanyaolu, A. et al. Comorbidity and its impact on patients with COVID-19. SN Compr. Clin. Med.2, 1069&#x2013;1076 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med.28, 1706&#x2013;1714 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Emergency use authorization 105. (2021). https://www.fda.gov/media/155049/download. Accessed 12 December 2022.</Citation></Reference><Reference><Citation>https://www.covid19treatmentguidelines.nih.gov/tables/management-of-nonhospitalized-adults-summary/. Accessed Janauary 6.</Citation></Reference><Reference><Citation>Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med.386, 509&#x2013;520 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 374, 1586&#x2013;1593 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevrioukova, I. F. &amp; Poulos, T. L. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc. Natl. Acad. Sci.107, 18422&#x2013;18427 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2973003</ArticleId><ArticleId IdType="pubmed">20937904</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit, D. et al. Long COVID: aiming for a consensus. Lancet Respirat. Med.10, 632&#x2013;634 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9067938</ArticleId><ArticleId IdType="pubmed">35525253</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff, D. et al. Short-term and long-term rates of Postacute Sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open.4, e2128568&#x2013;e2128568 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker, M. et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat. Commun.13, 1957 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 185, 881&#x2013;895e820 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly, Z., Bowe, B. &amp; Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med.28, 1461&#x2013;1467 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, H. et al. Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation? Front. Med. 9 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9596971</ArticleId><ArticleId IdType="pubmed">36314031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra, S. et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. ciac673 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9452095</ArticleId><ArticleId IdType="pubmed">35986628</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny, R. et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin. Infect. Dis. ciac443 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon, S. et al. Nirmatrelvir/ritonavir and risk of long COVID symptoms: A retrospective cohort study. Sci. Rep.13, 19688 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10640584</ArticleId><ArticleId IdType="pubmed">37951998</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Choi, T. &amp; Al-Aly, Z. Association of Treatment with Nirmatrelvir and the risk of Post&#x2013;COVID-19 Condition. JAMA Int. Med.183, 554&#x2013;564 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubai Health Authority. https://www.dha.gov.ae/en/media/news/762. Accessed 10/12/2023.</Citation></Reference><Reference><Citation>Dubai Health Authority. https://services.dha.gov.ae/sheryan/wps/portal/home/circular-details?circularRefNo=CIR-2021-00000039&amp;isPublicCircular=1&amp;fromHome=true. Accessed 1/02/2022.</Citation></Reference><Reference><Citation>Dubai Health Authority. https://www.dha.gov.ae/uploads/112021/ef299be5-9980-4389-9a31-80df9eb069fc.pdf, Accessed: 1/02/2022.</Citation></Reference><Reference><Citation>Sharif-Askari, S. Risk factors and early preventive measures for long COVID in non-hospitalized patients: Analysis of a large cohort in the United Arab Emirates. Public. Health. 230, 198&#x2013;206 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38574425</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine38 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal, N. R. et al. Real-world use of nirmatrelvir&#x2013;ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: A retrospective cohort study. Lancet. Infect. Dis. 23, 696&#x2013;705 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014040</ArticleId><ArticleId IdType="pubmed">36780912</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, K. L. et al. Population-based evaluation of the effectiveness of nirmatrelvir&#x2013;ritonavir for reducing hospital admissions and mortality from COVID-19. Can. Med. Assoc. J.195, E220 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9928441</ArticleId><ArticleId IdType="pubmed">36781188</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai, M. et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N. Engl. J. Med.388, 89&#x2013;91 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749618</ArticleId><ArticleId IdType="pubmed">36476720</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, C., Zhao, H., Esp&#xed;n, E. &amp; Tebbutt, S. J. Association of SARS-CoV-2 infection and persistence with long COVID. Lancet Respirat. Med.11, 504&#x2013;506 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171832</ArticleId><ArticleId IdType="pubmed">37178694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>